-I O Ellis Researcher Activity Profile

Research Author Detailed Information 

I O Ellis Publication Rate By Year

I O Ellis has published 1 paper(s) in 1992, 1 paper(s) in 1998, 5 paper(s) in 2002, 1 paper(s) in 2005, 1 paper(s) in 2006, 17 paper(s) in 2007, 18 paper(s) in 2008, for a total of 44 research publications in total.

I O Io Ellis Author Information

LAST NAME: ellis

FIRST NAME: I O

INITIALS: io

AFFILIATION:

Papers

I O Ellis's Publication Record

1. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Year Published: 2002
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham, UK.
2. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Year Published: 2005
Department of Histopathology, The Breast Unit, Nottingham City Hospital, University of Nottingham, Nottingham, UK. emadrakha@yahoo.com
3. Adenomyoepithelioma of the breast; a case report and literature review. Year Published: 2007
Cambridge Breast Unit, Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust, UK.
4. Reading the prognosis of the individual with breast cancer. Year Published: 2007
The Breast Institute, Nottingham City Hospital, Nottingham NG5 1PB, UK. wendy.bartlam@nuh.nhs.uk
5. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Year Published: 2007
The Breast Institute, Nottingham City Hospital, Nottingham NG5 1PB, UK. wendy.bartlam@nuh.nhs.uk
6. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. Year Published: 2007
CRUK Institute of Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK.
7. The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Year Published: 2007
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
8. The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Year Published: 2007
Department of Histopathology, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK.
9. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. Year Published: 2007
Molecular Medical Sciences, University of Nottingham, Department of Histopathology, Nottingham City Hospital NHS Trust. Nottingham University, Nottingham, UK.
10. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. Year Published: 2007
CRUK Institute of Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK.
11. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. Year Published: 2007
Radiology, Breast Institute, Nottingham City Hospital, Nottingham, UK.
12. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. Year Published: 2007
Molecular Medical Sciences, University of Nottingham, Department of Histopathology, Nottingham City Hospital NHS Trust. Nottingham University, Nottingham, UK.
13. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Year Published: 2007
Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK.
14. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Year Published: 2008
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK. hutchesonir@cf.ac.uk.
15. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Year Published: 2008
Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. aet21@cam.ac.uk.
16. Expression profiling technology: its contribution to our understanding of breast cancer. Year Published: 2008
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham and The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
17. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Year Published: 2007
Clinical Oncology, University of Nottingham, University Hospitals, City Hospital Campus, Nottingham, UK.
18. The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Year Published: 2007
Department of Histopathology, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK. andrew.lee@nuh.nhs.uk
19. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Year Published: 2008
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK. hutchesonir@cf.ac.uk.
20. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Year Published: 2008
Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. aet21@cam.ac.uk.
21. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Year Published: 2008
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK. hutchesonir@cf.ac.uk
22. The influence of Basal phenotype on the metastatic pattern of breast cancer. Year Published: 2008
Breast Institute, Nottingham City Hospital, Nottingham NG5 1PB, UK.
23. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. Year Published: 2007
Radiology, Breast Institute, Nottingham City Hospital, Nottingham, UK. andrew.evans@nuh.nhs.uk
24. False-negative assessment of oestrogen receptor on needle core biopsy of invasive carcinoma of the breast. Year Published: 2008
25. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Year Published: 2008
Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. aet21@cam.ac.uk
26. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Year Published: 2002
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham, UK.
27. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Year Published: 2002
Department of Histopathology, City Hospital, Nottingham, UK
28. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Year Published: 2007
Clinical Oncology, University of Nottingham, University Hospitals, City Hospital Campus, Nottingham, UK.
29. Expression profiling technology: its contribution to our understanding of breast cancer. Year Published: 2008
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.
30. False-negative assessment of oestrogen receptor on needle core biopsy of invasive carcinoma of the breast. Year Published: 2008
31. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Year Published: 2007
Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
32. Fibroadenomatoid hyperplasia: a cause of suspicious microcalcification on mammographic screening. Year Published: 1998
Department of Radiology, Nottingham City Hospital, United Kingdom.
33. Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? Year Published: 2006
Breast Institute, Nottingham International Breast Education Center and Nottingham City Hospital, Hucknall Rd., Nottingham NG5 1PB, United Kingdom.
34. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Year Published: 2008
Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK. kriskuli@landspitali.is.
35. Are triple-negative tumours and basal-like breast cancer synonymous? Year Published: 2008
Department of Histopathology, Nottingham City Hospital NHS Trust, University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK. Emad.Rakha@nuh.nhs.uk.
36. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Year Published: 2008
Cancer Research UK, Cambridge Research Institute, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. cb391@cam.ac.uk.
37. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Year Published: 2008
Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. sc10021@cam.ac.uk.
38. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Year Published: 2008
Cancer Research UK, Cambridge Research Institute, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. cb391@cam.ac.uk
39. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Year Published: 2008
Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. sc10021@cam.ac.uk
40. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Year Published: 2002
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham, UK.
41. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Year Published: 2002
Department of Histopathology, City Hospital, Nottingham, UK
42. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Year Published: 1992
Department of Histopathology, City Hospital, Nottingham, UK.
43. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Year Published: 2007
Department of Histopathology and Surgery, School of Molecular Medical Sciences, Nottingham University Hospitals National Health Service Trust and University of Nottingham, Nottingham, United Kingdom. emadrakha@yahoo.com
44. Expression profiling technology: its contribution to our understanding of breast cancer. Year Published: 2008
Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.